Khiron Life Sciences Corp. KHRNF KHRN A released its financial results for the fiscal year and quarter ended December 31, 2021.
2021 Financial Highlights:
-
Net loss of C$33.13 million ($25.67 million) compared to a net loss of C$24.04 million in 2020, an unfavorable increase of 37.81%.
-
Revenues of C$12.8 million compared to C$8.02 million in 2020
-
Adjusted EBITDA was a loss of C$17.38 million compared to a loss of C$18.76 million in 2020.
-
Gross profit before fair value adjustments C$4.91 million compared to CA$1.48 million in 2020, a favorable balance sheet increase of 231.75%.
Fourth quarter 2021 financial highlights:
-
Net loss of C$19.5 million compared to a net loss of C$2.37 million in the fourth quarter of 2020, an unfavorable increase of 722.78%.
-
Revenues of C$3.63 million compared to C$2.52 million in the fourth quarter of 2020
-
Adjusted EBITDA was a loss of C$5.65 million, compared to a loss of C$4.34 million in the fourth quarter of 2020.
-
Gross profit before fair value adjustments was C$1.08 million, compared to C$402,000 in the fourth quarter of 2020.
Related News
Cannabis dispensary roundup: Where to buy recreational marijuana in New Jersey, CBD spas and other store openings
Khiron Opens New Zerenia Clinic and Medical Cannabis Pharmacy in Colombia
How effective is medicinal cannabis as a treatment for chronic pain? Khiron’s clinical study reveals
